Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII (45)

Similar documents

CHEMOTHERAPY Table 1 Urinary excretion of mezlocillin Fig. 4 Urinary excretion of mezlocillin Fig. 3 Blood levels of mezlocillin

VOL.32 S-7 CHEMOTHERAPY Table 1 MIC of standard strains of CTRX Fig. 2 Cumulative curves of MIC S. aureus (26 strains )

CHEMOTHERAPY JUN Citrobacter freundii 27, Enterobacter aerogenes 26, Enterobacter cloacae 27, Proteus rettgeri 7, Proteus inconstans 20, Proteus

VOL. 34 S-2 CHEMOTH8RAPY 913

988 CHEMOTHERAPY NOV. 1971

CHEMOTHERAPY

VOL. 23 NO. 3 CHEMOTHERAPY 1067 Table 2 Sensitivity of gram positive cocci isolated from various diagnostic materials Table 3 Sensitivity of gram nega

CHEMOTHERAPY FEB Table 1. Activity of cefpirome and others against clinical isolates

CHEMOTHERAPY Fig. 1 Chemical structure of CXM-AX

VOL.30 S-1 CHEMOTHERAPY Table 1 Antibacterial activity of CTT against standard strains Table 2 Antibacterial activity of CTT against standard strains

VOL. 40 S- 1 Table 1. Susceptibility of methicillin-resistant Staphylococcus aureus to meropenem Table 2. Coagulase typing of methicillin-resistant St

VOL.42 S-1


CHEMOTHERAPY JUNE 1993 Table 1. Background of patients in pharmacokinetic study

VOL. 23 NO. 3 CHEMOTHERAPY 1379 Table 1 Susceptibility of clinical isolated strains to Tobramycin

Fig. 1 Chemical structure of KW-1070


CHEMOTHERAPY NOV S. aureus, S. epidermidis, E. coli, K. pgeumoniae, E. cloacae, S. marcescens, P. mirabilis, Proteus, P. aeruginosa Inoculum siz


coccus aureus Corynebacterium sp, Haemophilus parainfluenzae Klebsiella pneumoniae Pseudornonas aeruginosa Pseudomonas sp., Xanthomonas maltophilia, F

Jan THE JAPANESE JOURNAL OF ANTIBIOTICS XL-1 Table 1. Outline of administering doses, routes and sampling times *: 4 ml/hr/kg Bacillus subtilis

CHEMOTHERAPY MAY. 1988

CHEMOTHERAPY FEB Table 1 Background of volunteers

Clinical studies on Cef triaxone in the field of oral surgery JIRO SASAKI,*1 MASATAKA UEMATSU,*l AKIHIRO KANEKO,*1 YOSHIHIDE OHTA,*1 KAZUO SHIIKI,*2 T

Experimental and Clinical Studies of Pregnant Hypertension Takashi SHIMAZU Department of Obstetrics and Gynecology, Osaka City University Medical Scho

Key words : 7432-S, Oral cephem, Urinary tract infection Fig. 1. Chemical structure of 7432-S.


Fig. 1 Chemical structure of DL-8280

CHEMOTHERAPY APR Fig. 2 The inactivation of aminoglycoside antibiotics by PC-904 Fig. 3 Serum concentration of PC-904 (1) Fig. 4 Urinary recover

VOL.35 S-2 CHEMOTHERAPY Table 1 Sex and age distribution Table 2 Applications of treatment with carumonam Table 3 Concentration of carumonam in human

VOL. 20 NO. 5 CHEMOTHERAPY Methoxy-4-sulfanilamidopyrimidine (OS-3376) Sulfadimethoxine (SDM) Table 1. In vitro antibacterial activities of OS-3

CHEMOTHERAPY SEPT. 1970

CHEMOTHERAPY Table 1 Clinical effect of Sultamicillin



Table 1. Antibacterial activitiy of grepafloxacin and other antibiotics against clinical isolates





Fig. 1 Chemical structure of norfioxacin (AM-715)

2108 CHEMOTHERAPY SEPT Table 1 Antimicrobial spectrum Fig. 1

epidermidis, Enterococcus faecalis, Enterococcus Klebsiella pneumoniae, Proteus mirabilis, indolepositive Proteus spp., Enterobacter spp., Serratia

Fig.1 Chemical structure of BAY o 9867

Staphylococcus sp. K.pneumoniae P.mirabilis C.freundii E. cloacae Serratia sp. P. aeruginosa ml, Enterococcus avium >100ƒÊg/ml

VOL. 36 S-3 CHEMOTHERAPY 437



1272 CHEMOTHERAPY MAR. 1975

VOL.27 CHEMOT S-1 HERAPY 185 に感 性 を示 して い たが,臨 床 的 に は無 効 で あ った 本 症 る 細 菌学 的 に も検 討 した が,起 炎菌 と考 え られ る細 菌 を 例 で は 基礎 疾 患 と して縦 隔 洞腫 瘍 が あ り,既 に 副 腎


CHEMOTHERAPY DEC Table 1 Antibacterial spectra of T-1982, CTT, CMZ, CTX, CPZ and CEZ 106 CFU/ml Note: P; Peptococcus, S; Streptococcus, G; Gaffk

Fig.2. Sensitivity distribution of clinical isolates of S. epidermidis (24 strains, 106 CFU/ml) Staphylococcus aureus Staphylococcus epider- midis Ent

Table 1. Antibacterial spectrum SBT ABPC ABPC CPZ : sulbactamiampicillin : ampicillin : cefoperazone

日本化学療法学会雑誌第51巻第2号

Table1MIC of BAY o 9867 against standard strains


VOL. 43 NO. 4

VOL.39 S-3

CHEMOTHERAPY DEC (NFLX), ofloxacin (OFLX), ciprofloxacin (CPFX) Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Enterococcus faecali


Visual Evaluation of Polka-dot Patterns Yoojin LEE and Nobuko NARUSE * Granduate School of Bunka Women's University, and * Faculty of Fashion Science,

CHEMOTHERAPY JUNE 1986

CHEMOTHERAPY OCT Fig. 1 Chemical structure of CVA-K

pneumoniae 30, C. freundii 32, E. aerogenes 27, E. cloacae 32, P. mirabilis 31, P. vulgaris 34, M. morganii 32, S. marcescens 31, H. influenzae 27, P.

Key words: E. coli O 157: H7, fosfomycin, verotoxin, mouse infection

CHEMOTHERAPY APR Fig. 1 Chemical structure of cefotetan (CTT, YM09 Molecular formula (Molecular weight) C17H15N7Na2OS4(619.57)

CHEMOTHERAPY

Fig. 1 Chemical structure of TE-031 Code number: TE-031 Chemical name: (-) (3R, 4S, 5S, 6R, 7R, 9R, 11R, 12R, 13S, 14R)-4-[(2, 6-dideoxy-3-C-methyl-3-

VOL. 37 NO. 3 Key words: Drug allergy, LMIT, Penams, Cephems, Cross-reactivity

Clostridium difficile ciprofloxacin, ofloxacin, norfloxacin Bifidobacterium Lactobacillus Lactobacillus Bacteroides fragilis B. fragilis C. difficile

THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec LVFX 100 mg 3 / mg 2 / LVFX PK PD mg mg 1 1 AUC/MIC

日本化学療法学会雑誌第59巻第5号

CHEMOTHERAPY Fig. 1 Body weight changes of pregnant mice treated orally with AM- 715 Day of sestation

VOL.47 NO.5 Table 1. Susceptibility distribution of Ĉ- lactams against clinical isolates of MRSA MRSA: rnethicillin- resistant Staphylococcus aureus

CHEMOTHERAPY aureus 0.10, Enterococcus faecalis 3.13, Escherichia coli 0.20, Klebsiella pneumoniae, Enterobacter spp., Serratia marcescens 0.78, Prote


THE JAPANESE JOURNAL OF ANTIBIOTICS 65 6 Dec DNA 2, , % 1.65% 1.17% 90% 9 Escherichia coli -

semen quality or those without WBC in semen. In the patients with azoospermia and normal FSH levels (normogonadotropic azzospermia), the antibody (IgG

CHEMOTHERAPY APR. 1982

Effect of Trimoprostil on Gastric Secretion Takeshi KAWAMURA * Hiroko EBINA * Fumiaki KOIZUMI * and Akira ISHIMORI * *Department of Clinical and Labor

CHEMOTHERAPY JUNE 1987 Table1 Media used *BHIB, brain heart infusion broth (Difco); /3 -NAD, S -nicotinamidoadeninedinucleotide (Sigma Chemical Co.);


A Nutritional Study of Anemia in Pregnancy Hematologic Characteristics in Pregnancy (Part 1) Keizo Shiraki, Fumiko Hisaoka Department of Nutrition, Sc

CHEMOTHERAPY MAY 1988

研修コーナー

CHEMOTHERAPY SEPT. 1991

THE JAPANESE JOURNAL OF ANTIBIOTICS 48-8 Enterococcus avium 5Š, Corynebacterium xerosis 10Š, Corynebacterium pseudodiphtheriticum 10Š, Corynebacterium

The Journal of the Japan Academy of Nursing Administration and Policies Vol 7, No 2, pp 19 _ 30, 2004 Survey on Counseling Services Performed by Nursi



400 CHEMOTHERAPY JAN Table 1 Cases of drop outs



明海大学歯学雑誌　３７‐２／１．秦泉寺

日本化学療法学会雑誌第53巻第S-3号


Key words : candidemia, endotoxin, D-arabinitol, Candida antigen, serological examination


Transcription:

Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 2305(45)

2306(46) THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 Dec.

Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 2307(47)

2308(48) THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 Dec.

Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 2309(49) Fig.2. Tissue concentration of intrapelvic genital organs after intravenous drip infusion of CTRX 1 g for 1 hour

2310(50) THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 Dec.

Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 2311(51) Fig.3. Tissue concentration of intrapelvic genital organs after intravenous drip infusion of CTRX 1 g for 30 minutes

2312(52) THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 Dec. Fig.4. Concentrations of CTRX in intrapelvic dead space exudate and concentrations required to inhibit 80% of clinical isolates (1g, i.v.) Table 4. Therapeutic results of CTRX

Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 2313(53) Table4. (Continued)

2314(54) THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 Dec. Table5. Clinical response to CTRX (1g x 2/day) Fig.5. Case 2, R.N., 31 y, 50 kg, Endometritis Fig.6. Case 3, Y.M., 36 y, 47 kg, Endometritis

Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 Fig.7. Case 4, K.T., 23y, 64kg, Endometritis Fig.8. Case 8, U.K., 20y, 60kg, Endometritis Fig.9. Case 13, T.Y., 40y, 51kg, Parametritis Fig.10. Case 5, K.M., 43y, 50kg, Endometritis, Adnexal abscess

THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 Dec. Fig.11. Case 6, Y.T., 34y, 78kg, Puerperal intrauterine infection Fig.12. Case 14, M.I., 26y, 60kg, Puerperal fever Fig.13. Case 1, T.O., 49y, 49 kg, Abdominal wall abscess

Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 2317(57) Table6. Bacteriological response to CTRX(1g ~2/day) Eliminated+Replaced/ Eliminated+ Decreased+ Unchanged+ Replaced

THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 Dec.

Dec. THE JAPANESE JOURNAL OF ANTIBIOTICS XXXVII-12 3) MCNAMARA, P. J.; K. STOECKEL & W. H. ZIEGLER : Pharmacokinetics of ceftriaxone following intravenous administration of a 3 g dose. Eur. J. Clin. Pharmacol. 22: 71 `75, 1982 4) ARISAWA, M.; J. OHSHIMA, E. OHSAWA, H. B. MARUYAMA, Y. SEKINE & S. MITSUHASHI: Bacteriological comparison of the activities of ceftriaxone, a new long-acting cephalosporin, with those of other new cephalosporins. Chem. Pharm. Bull. 30: 2544 `2554, 1982 PHARMACOKINETICS AND CLINICAL STUDIES ON CEFTRIAXONE IN THE FIELD OF OBSTETRICS AND GYNECOLOGY NANKUN CHO, HIROKO WATANABE, KIYOSHI YOSHIDA, SHUICHI MORIYAMA, HITOSHI TAKEDA and AKIMICHI TSUKAMOTO Department of Obstetrics and Gynecology, School of Medicine, Showa University Department KANGO FUKUNAGA of Obstetrics and Gynecology, Ohira Hospital KATSUAKI KUNII Department of Obstetrics and Gynecology, Kunii Hospital YOSHIHIRO KOMORIYAMA Department of Obstetrics and Gynecology, Fukushima Red-cross Hospital Ceftriaxone (Ro 13-9904, CTRX), a new cephem antibiotic, was studied in the field of obstetrics and gynecology, and the following results were obtained. 1. The absorption and tissue penetration of CTRX into intrapelvic genital organs were good. The peak serum level in the uterine artery after a single intravenous injection and that after an intravenous drip infusion for 30-60 minutes, both with 1 g, were 162.5 pg/ml and 84.4-93.8 pg/ml, respectively. High concentrations were obtained also in genital organ tissues; the maximum concentration was 93.8 pg/g by intravenous injection and 56.3 59.4 pg/g by intravenous drip infusion. Changes in the tissue concentration were similar to those in the serum, the level over MICH against main pathogenic organisms being maintained for a long time. 2. The penetration of CTRX into intrapelvic dead space exudate was good. The level reached a peak of 18.8 pg/ml 2 hours after an intravenous injection with 1 g and 13.3 pg/ml after 12 hours, while the level over MIC80 against main pathogenic organisms was maintained for a long time. 3. CTRX was effective in 15 out of 16 cases (93.8%) with gynecoobstetric infections such as intrauterine, intrapelvic, adnexal infections, and postoperative wound infections, administered with 1 g twice a day. No side effects were observed.

2024 © docsplayer.net プライバシー | 利用規約 | フィードバック